ATE396724T1 - 1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer - Google Patents

1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer

Info

Publication number
ATE396724T1
ATE396724T1 AT05701307T AT05701307T ATE396724T1 AT E396724 T1 ATE396724 T1 AT E396724T1 AT 05701307 T AT05701307 T AT 05701307T AT 05701307 T AT05701307 T AT 05701307T AT E396724 T1 ATE396724 T1 AT E396724T1
Authority
AT
Austria
Prior art keywords
thieno
kinase
inhibitors
pyrazole derivatives
pyrazole
Prior art date
Application number
AT05701307T
Other languages
English (en)
Inventor
Daniele Fancelli
Simona Bindi
Mario Varasi
Paola Vianello
Sergio Vioglio
Dania Tesei
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of ATE396724T1 publication Critical patent/ATE396724T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05701307T 2004-02-03 2005-02-02 1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer ATE396724T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54145204P 2004-02-03 2004-02-03

Publications (1)

Publication Number Publication Date
ATE396724T1 true ATE396724T1 (de) 2008-06-15

Family

ID=34837492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701307T ATE396724T1 (de) 2004-02-03 2005-02-02 1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer

Country Status (37)

Country Link
US (2) US8138217B2 (de)
EP (1) EP1711177B1 (de)
JP (1) JP4908233B2 (de)
KR (1) KR20060124734A (de)
CN (1) CN1946395B (de)
AP (1) AP2006003701A0 (de)
AR (1) AR047531A1 (de)
AT (1) ATE396724T1 (de)
AU (1) AU2005210114B2 (de)
BR (1) BRPI0507375A (de)
CA (1) CA2555262C (de)
CR (1) CR8546A (de)
CY (1) CY1108246T1 (de)
DE (1) DE602005007181D1 (de)
DK (1) DK1711177T3 (de)
DO (1) DOP2005000014A (de)
EA (1) EA011032B1 (de)
EC (1) ECSP066767A (de)
ES (1) ES2307144T3 (de)
GE (1) GEP20094633B (de)
GT (1) GT200500020A (de)
IL (1) IL177141A0 (de)
MA (1) MA28429B1 (de)
MX (1) MXPA06008787A (de)
NO (1) NO20063768L (de)
NZ (1) NZ548896A (de)
PA (1) PA8622801A1 (de)
PE (1) PE20051095A1 (de)
PL (1) PL1711177T3 (de)
PT (1) PT1711177E (de)
SI (1) SI1711177T1 (de)
TN (1) TNSN06244A1 (de)
TW (1) TW200526204A (de)
UA (1) UA86223C2 (de)
UY (1) UY28738A1 (de)
WO (1) WO2005074922A1 (de)
ZA (1) ZA200606179B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530573B1 (de) * 2002-07-25 2008-03-19 Pfizer Italia S.r.l. Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
JP5303271B2 (ja) 2005-07-19 2013-10-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物
US20090306169A1 (en) * 2005-10-06 2009-12-10 Brandish Philip E Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2007380B1 (de) 2006-03-30 2011-09-14 Nerviano Medical Sciences S.r.l. Verwendung eines kinasehemmers zur behandlung von bestimmten resistenten tumoren
WO2007138017A1 (en) * 2006-05-31 2007-12-06 Nerviano Medical Sciences S.R.L. 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors
FR2904626B1 (fr) * 2006-08-03 2008-09-19 Sanofi Aventis Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
KR100923540B1 (ko) 2007-11-23 2009-10-27 한국과학기술연구원 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
AR071780A1 (es) * 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
JP2012521429A (ja) * 2009-03-23 2012-09-13 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
ES2929759T3 (es) * 2012-04-05 2022-12-01 Nerviano Medical Sciences Srl Nuevos agentes alquilantes
CN110945002B (zh) * 2017-08-01 2021-12-24 正大天晴药业集团股份有限公司 作为RORγ抑制剂的双环化合物
BR112020010905A2 (pt) * 2017-11-30 2020-11-17 Hanmi Pharm. Co., Ltd. compostos, composição farmacêutica e uso de um composto ou da composiçao farmacêutica
CN113072562B (zh) * 2021-04-06 2022-01-14 山东大学 一种GSK-3β抑制剂及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3763409D1 (de) 1986-02-19 1990-08-02 Duphar Int Res Thio-verbindungen und ihre wirkung als fungizide.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
MXPA02001498A (es) 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
CA2416527C (en) * 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2002215053A1 (en) 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
US20040116497A1 (en) 2001-01-26 2004-06-17 Gabriella Traquandi Chromane derivatives, process for their preparation and their use as antitumor agents
KR20040047869A (ko) 2001-09-26 2004-06-05 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 아미노인다졸 유도체, 이의제조방법 및 이를 함유하는 약제학적 조성물
WO2003097610A1 (en) * 2002-05-17 2003-11-27 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004007504A1 (en) * 2002-07-17 2004-01-22 Pharmacia Italia S.P.A. Heterobicyclic pyrazole derivatives as kinase inhibitors
EP1530573B1 (de) * 2002-07-25 2008-03-19 Pfizer Italia S.r.l. Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
US20050026984A1 (en) * 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products

Also Published As

Publication number Publication date
PL1711177T3 (pl) 2008-11-28
PT1711177E (pt) 2008-09-04
JP4908233B2 (ja) 2012-04-04
NZ548896A (en) 2010-05-28
DE602005007181D1 (de) 2008-07-10
WO2005074922A1 (en) 2005-08-18
TW200526204A (en) 2005-08-16
PA8622801A1 (es) 2005-11-25
CY1108246T1 (el) 2014-02-12
IL177141A0 (en) 2006-12-10
CR8546A (es) 2007-05-30
TNSN06244A1 (fr) 2007-12-03
US20050187209A1 (en) 2005-08-25
MA28429B1 (fr) 2007-02-01
AR047531A1 (es) 2006-01-25
US8138217B2 (en) 2012-03-20
DOP2005000014A (es) 2006-08-15
UA86223C2 (uk) 2009-04-10
ZA200606179B (en) 2008-02-27
JP2007520513A (ja) 2007-07-26
CA2555262A1 (en) 2005-08-18
GT200500020A (es) 2005-09-06
BRPI0507375A (pt) 2007-07-10
EA011032B1 (ru) 2008-12-30
AU2005210114A1 (en) 2005-08-18
EP1711177B1 (de) 2008-05-28
MXPA06008787A (es) 2007-01-19
CN1946395A (zh) 2007-04-11
SI1711177T1 (sl) 2008-10-31
PE20051095A1 (es) 2005-12-31
CA2555262C (en) 2014-10-14
HK1101343A1 (en) 2007-10-18
EA200601418A1 (ru) 2006-12-29
KR20060124734A (ko) 2006-12-05
UY28738A1 (es) 2005-09-30
EP1711177A1 (de) 2006-10-18
GEP20094633B (en) 2009-03-10
DK1711177T3 (da) 2008-09-29
AP2006003701A0 (en) 2006-08-31
NO20063768L (no) 2006-11-02
ECSP066767A (es) 2006-11-24
US20120165311A1 (en) 2012-06-28
US8481584B2 (en) 2013-07-09
AU2005210114B2 (en) 2011-07-14
CN1946395B (zh) 2014-04-02
ES2307144T3 (es) 2008-11-16

Similar Documents

Publication Publication Date Title
HUS1900034I1 (hu) 6,7-telítetlen-7-karbamoil-szubsztituált morfinán-származékok
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE525377T1 (de) Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE501138T1 (de) Thiophenderivate als chk-1-inhibitoren
NO20054224D0 (no) Nye 2-pyridinkarboksamidderivater
ATE352550T1 (de) Chinazolinderivate
ATE420066T1 (de) Amidoacetonitrilderivate
ATE394399T1 (de) Tetrahydropyridoindolderivate
ATE540935T1 (de) Chinazolinderivate
DE602004012154D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
ATE383361T1 (de) Pyrrazolopyrimidinderivate
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
IS2656B (is) Nýjar besímídasólafleiður
ATE417830T1 (de) Sulfonylbenzimidazolderivate
ATE354365T1 (de) N-thiazol-2-yl-benzamid-derivate
DE602005007181D1 (de) 1h-thieno 2,3-c-pyrazol-derivate als kinase-i-hemmer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1711177

Country of ref document: EP

EEIH Change in the person of patent owner